Treatment of subnormal bone mineral density
AssigneeGenelabs Technologies, Inc.
InventorKenneth E. Schwartz
Life of this patent
Estimating the term…
Abstract
A method of treating an individual to increase the individual's bone mineral density (BMD) is disclosed. The method includes co-administering a calcitonin-like agent and a DHEA-like agent. Also disclosed are methods for potentiating the effect of treatment with a calcitonin-like agent on BMD and for increasing BMD in an individual being treated with DHEA, e.g., for treatment of systemic lupus erythematosus (SLE).
Claims25
A pharmaceutical formulation for inhibiting bone loss in an individual comprising an effective amount DHEA (prasterone) and an effective amount of a calcitonin-like agent;
- wherein:
- at least about 85% of the DHEA is present as form I polymorph, form II polymorph, or a combination thereof;
- and
- the calcitonin-like agent is selected from the group consisting of salmon or mammalian calcitonin, calcitonin gene-related peptide (CGRP), and native amylin.
A pharmaceutical formulation for inhibiting bone loss in an individual consisting of an effective amount of a dehydroepiandrosterone (DHEA)-like agent, an effective amount of a calcitonin-like agent, and a physiologically acceptable carrier, excipient, diluent, or buffer;
- wherein:
- the DHEA-like agent is selected from the group consisting of DHEA (prasterone), 7-alpha-hydroxy-DHEA, 5-androstene-3-beta, 17-beta-diol, and 4 androstene diol;
- and
- the calcitonin-like agent is selected from the group consisting of salmon or mammalian calcitonin, calcitonin gene-related peptide (CGRP), and native amylin.
Dependencies are inferred from the claim text.